Opko健康 OPK 深 滬
等待開盤 08-01 09:30:00 美东时间
1.32
-0.015
-1.12%
華盛通- 最 高1.35
- 今 開1.33
- 成交量 282.62万股
- 最 低 1.305
- 昨 收 1.335
- 總市值 9.85亿
- 52周最高 1.73
- 市盈率 靜 --
- 換手率 0.38%
- 52周最低 0.9769
- 委 比 49.40%
- 總股本 7.46亿
- 歷史最高 19.20
- 量 比 0.26
- 振 幅 3.37%
- 歷史最低 0.8516
- 每 手 1
- 風險率 0.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | AI基建股IOND首日升近26%，为21年来最大直接上市项目；Lucid劲升21%
AI基建股IOND首日升近26%，为21年来最大直接上市项目；医药股PMN飙升23%，阿尔茨海默病药物试验结果积极；Lucid劲升21%，获沙特首富1.3亿美元投资>>
07-29 19:00
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Celestica Inc (NYSE:CLS) rose sharply in pre-market trading after the company posted its second-quarter results, beating analyst estimates on the top and bottom lines. Celestica reported quarterly earnings of $2.54 per share, which beat the Street estimate of $2.30 by 10.43%, according to ...
07-28 17:01
美股夜盘 | Polar Power涨42.86%，因立夫涨32.93%
Edible Garden涨-8.59%；艾马克技术涨-7.03%；Ethos Technologies涨-6.98%
07-28 08:05
OPKO Health Raises FY2026 Sales Guidance from $530.000M-$560.000M to $560.000M-$585.000M vs $534.899M Est
OPKO Health (NASDAQ:OPK) raises FY2026 sales outlook from $530.000 million-$560.000 million to $560.000 million-$585.000 million vs $534.899 million estimate.
07-28 04:07
OPKO Health Sees Q3 Sales $131.000M-$142.000M vs $134.650M Est
OPKO Health (NASDAQ:OPK) sees Q3 sales of $131.000 million-$142.000 million vs $134.650 million analyst estimate.
07-28 04:07
OPKO Health Q2 EPS $(0.01), Sales $163.500M Beat $131.233M Estimate
OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. This is a 85.71 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $163.500 million whi...
07-28 04:06
Entera Bio prices $275M private placement
Entera Bio (NASDAQ:ENTX) said on Monday it priced an oversubscribed $275M private placement led by existing investor BVF Partners, with participation from several healthcare-focused institutional inve...
07-27 20:59
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
<p>OPKO Health announced it will report second-quarter 2026 operating and financial results on July 27, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET. Participants can pre-register via a link to receive a unique PIN or join by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast is also available through OPKO’s Investor Relations. A telephone replay will be available until August 3, 2026, by dia...
07-23 16:30
Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for o...
06-16 20:44
